Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Scleroderma, Systemic | 19 | 2023 | 344 | 7.600 |
Why?
|
Skin Ulcer | 9 | 2021 | 130 | 4.720 |
Why?
|
HIV Infections | 161 | 2024 | 17354 | 2.880 |
Why?
|
Anti-HIV Agents | 84 | 2023 | 4527 | 2.830 |
Why?
|
Raynaud Disease | 6 | 2022 | 79 | 2.750 |
Why?
|
Fingers | 8 | 2021 | 507 | 2.680 |
Why?
|
HIV-1 | 80 | 2023 | 6863 | 1.910 |
Why?
|
CD4 Lymphocyte Count | 63 | 2023 | 2571 | 1.790 |
Why?
|
HIV Protease Inhibitors | 24 | 2022 | 432 | 1.630 |
Why?
|
Antiretroviral Therapy, Highly Active | 39 | 2023 | 1897 | 1.520 |
Why?
|
Reverse Transcriptase Inhibitors | 29 | 2023 | 621 | 1.410 |
Why?
|
Ritonavir | 26 | 2022 | 329 | 1.410 |
Why?
|
Viral Load | 53 | 2024 | 3332 | 1.400 |
Why?
|
Nevirapine | 23 | 2023 | 273 | 1.350 |
Why?
|
Zidovudine | 27 | 2021 | 624 | 1.090 |
Why?
|
Infectious Disease Transmission, Vertical | 25 | 2021 | 1352 | 1.060 |
Why?
|
Antiviral Agents | 18 | 2024 | 3060 | 1.010 |
Why?
|
RNA, Viral | 51 | 2023 | 2846 | 1.000 |
Why?
|
Tuberculosis | 10 | 2024 | 2017 | 0.950 |
Why?
|
Pregnancy Complications, Infectious | 27 | 2023 | 2151 | 0.940 |
Why?
|
Anti-Retroviral Agents | 20 | 2023 | 1784 | 0.900 |
Why?
|
Osteomyelitis | 3 | 2021 | 407 | 0.810 |
Why?
|
Calcinosis | 3 | 2019 | 1469 | 0.790 |
Why?
|
Vascular Diseases | 3 | 2018 | 1161 | 0.700 |
Why?
|
Acquired Immunodeficiency Syndrome | 22 | 2023 | 2199 | 0.700 |
Why?
|
Microscopic Angioscopy | 2 | 2016 | 20 | 0.680 |
Why?
|
Erectile Dysfunction | 1 | 2023 | 444 | 0.670 |
Why?
|
Clinical Trials as Topic | 22 | 2019 | 8002 | 0.670 |
Why?
|
Models, Statistical | 15 | 2017 | 5079 | 0.670 |
Why?
|
Takayasu Arteritis | 1 | 2020 | 105 | 0.640 |
Why?
|
Randomized Controlled Trials as Topic | 20 | 2023 | 10212 | 0.640 |
Why?
|
Drug Resistance, Viral | 14 | 2024 | 862 | 0.640 |
Why?
|
Latent Tuberculosis | 4 | 2023 | 224 | 0.640 |
Why?
|
Hand Joints | 1 | 2019 | 58 | 0.620 |
Why?
|
Tuberculosis, Multidrug-Resistant | 6 | 2023 | 934 | 0.590 |
Why?
|
Humans | 297 | 2024 | 761596 | 0.580 |
Why?
|
Connective Tissue Diseases | 2 | 2016 | 285 | 0.530 |
Why?
|
Giant Cell Arteritis | 1 | 2020 | 306 | 0.530 |
Why?
|
Thermography | 1 | 2016 | 63 | 0.530 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2020 | 4016 | 0.510 |
Why?
|
Hemoglobinopathies | 1 | 2016 | 99 | 0.500 |
Why?
|
Central Nervous System Stimulants | 1 | 2022 | 1177 | 0.450 |
Why?
|
Botswana | 16 | 2023 | 1048 | 0.450 |
Why?
|
Diagnostic Tests, Routine | 3 | 2020 | 787 | 0.450 |
Why?
|
Adult | 140 | 2024 | 221210 | 0.450 |
Why?
|
HIV | 13 | 2024 | 1582 | 0.440 |
Why?
|
Female | 179 | 2024 | 392705 | 0.430 |
Why?
|
Tuberculosis, Pulmonary | 5 | 2023 | 832 | 0.430 |
Why?
|
Research Design | 10 | 2021 | 6180 | 0.430 |
Why?
|
Mass Casualty Incidents | 1 | 2015 | 179 | 0.420 |
Why?
|
HIV Seropositivity | 5 | 2022 | 960 | 0.420 |
Why?
|
Blood Coagulation Disorders | 1 | 2016 | 350 | 0.420 |
Why?
|
Copper | 1 | 2015 | 369 | 0.400 |
Why?
|
Male | 149 | 2024 | 360846 | 0.400 |
Why?
|
Fibrosis | 2 | 2020 | 2049 | 0.390 |
Why?
|
Selenium | 1 | 2015 | 417 | 0.390 |
Why?
|
Myositis | 1 | 2015 | 271 | 0.390 |
Why?
|
Isoniazid | 4 | 2024 | 283 | 0.390 |
Why?
|
Didanosine | 12 | 2007 | 151 | 0.380 |
Why?
|
Focus Groups | 3 | 2023 | 1415 | 0.380 |
Why?
|
Quality of Life | 8 | 2022 | 13367 | 0.370 |
Why?
|
Lamivudine | 9 | 2021 | 366 | 0.360 |
Why?
|
Rheumatic Diseases | 2 | 2016 | 649 | 0.360 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1303 | 0.360 |
Why?
|
Troponin I | 1 | 2015 | 651 | 0.350 |
Why?
|
Risk-Taking | 3 | 2015 | 1038 | 0.350 |
Why?
|
Cost of Illness | 1 | 2020 | 1937 | 0.350 |
Why?
|
Influenza, Human | 5 | 2020 | 1521 | 0.350 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2013 | 857 | 0.340 |
Why?
|
Troponin T | 1 | 2015 | 780 | 0.340 |
Why?
|
Sex Characteristics | 3 | 2020 | 2639 | 0.340 |
Why?
|
Pyrimidinones | 7 | 2011 | 385 | 0.330 |
Why?
|
Rifampin | 5 | 2023 | 339 | 0.330 |
Why?
|
Drug Therapy, Combination | 33 | 2024 | 6312 | 0.330 |
Why?
|
Data Interpretation, Statistical | 5 | 2016 | 2691 | 0.330 |
Why?
|
Reperfusion Injury | 1 | 2016 | 1023 | 0.330 |
Why?
|
Ribavirin | 4 | 2019 | 395 | 0.320 |
Why?
|
Treatment Failure | 7 | 2019 | 2643 | 0.320 |
Why?
|
Oseltamivir | 3 | 2020 | 75 | 0.320 |
Why?
|
Typhoid Fever | 2 | 2021 | 194 | 0.310 |
Why?
|
Treatment Outcome | 60 | 2023 | 64685 | 0.310 |
Why?
|
Incidence | 15 | 2023 | 21355 | 0.310 |
Why?
|
Radiography | 1 | 2019 | 6965 | 0.300 |
Why?
|
Piperazines | 8 | 2020 | 2523 | 0.290 |
Why?
|
Qualitative Research | 4 | 2023 | 3025 | 0.290 |
Why?
|
Monitoring, Physiologic | 2 | 2010 | 1779 | 0.290 |
Why?
|
Drug Dosage Calculations | 1 | 2008 | 117 | 0.290 |
Why?
|
Sample Size | 2 | 2021 | 841 | 0.290 |
Why?
|
Plasma | 5 | 2019 | 586 | 0.290 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2022 | 3708 | 0.280 |
Why?
|
Pyrimidines | 9 | 2022 | 3028 | 0.280 |
Why?
|
Middle Aged | 65 | 2024 | 220921 | 0.280 |
Why?
|
Infant, Newborn | 35 | 2024 | 26202 | 0.270 |
Why?
|
Biometry | 7 | 2006 | 563 | 0.270 |
Why?
|
Mycobacterium tuberculosis | 3 | 2023 | 1914 | 0.270 |
Why?
|
Wounds and Injuries | 1 | 2019 | 2492 | 0.270 |
Why?
|
Infant | 47 | 2024 | 36193 | 0.260 |
Why?
|
Self Report | 3 | 2021 | 3725 | 0.260 |
Why?
|
Patient Participation | 1 | 2015 | 1445 | 0.260 |
Why?
|
Antitubercular Agents | 5 | 2024 | 1375 | 0.260 |
Why?
|
Antibodies, Viral | 6 | 2024 | 3156 | 0.260 |
Why?
|
Benzoxazines | 4 | 2020 | 316 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3206 | 0.250 |
Why?
|
Observation | 1 | 2007 | 310 | 0.250 |
Why?
|
Pregnancy | 40 | 2024 | 29890 | 0.240 |
Why?
|
Anemia | 4 | 2023 | 1509 | 0.240 |
Why?
|
Adaptation, Psychological | 3 | 2023 | 2629 | 0.240 |
Why?
|
Hepatitis C | 4 | 2019 | 1584 | 0.240 |
Why?
|
Premature Birth | 4 | 2024 | 1782 | 0.240 |
Why?
|
Bayes Theorem | 7 | 1999 | 2330 | 0.230 |
Why?
|
Stroke | 3 | 2020 | 9758 | 0.230 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2022 | 4369 | 0.230 |
Why?
|
Diagnostic Errors | 2 | 2015 | 1265 | 0.230 |
Why?
|
Patient Selection | 5 | 2019 | 4244 | 0.230 |
Why?
|
Endothelium, Vascular | 1 | 2016 | 4431 | 0.220 |
Why?
|
Cluster Analysis | 2 | 2021 | 2707 | 0.220 |
Why?
|
Meta-Analysis as Topic | 5 | 1997 | 1380 | 0.220 |
Why?
|
Survival Analysis | 7 | 2014 | 10090 | 0.220 |
Why?
|
Energy Intake | 4 | 2015 | 2134 | 0.220 |
Why?
|
Contact Tracing | 3 | 2022 | 271 | 0.220 |
Why?
|
Disability Evaluation | 3 | 2020 | 1836 | 0.210 |
Why?
|
Ulcer | 2 | 2021 | 204 | 0.210 |
Why?
|
Endpoint Determination | 3 | 2014 | 590 | 0.210 |
Why?
|
Adrenergic Antagonists | 1 | 2022 | 26 | 0.210 |
Why?
|
Cardiomyopathies | 1 | 2015 | 1964 | 0.210 |
Why?
|
Scleroderma, Limited | 1 | 2022 | 8 | 0.210 |
Why?
|
Severity of Illness Index | 15 | 2020 | 15843 | 0.210 |
Why?
|
Scleroderma, Diffuse | 1 | 2022 | 18 | 0.210 |
Why?
|
Iron, Dietary | 1 | 2023 | 148 | 0.210 |
Why?
|
Probability | 6 | 2016 | 2477 | 0.210 |
Why?
|
Nelfinavir | 3 | 2008 | 68 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.200 |
Why?
|
Receptors, Chemokine | 4 | 2008 | 652 | 0.200 |
Why?
|
Fibrinolytic Agents | 2 | 2012 | 2084 | 0.200 |
Why?
|
Breast Feeding | 4 | 2017 | 1360 | 0.200 |
Why?
|
Smoke | 2 | 2014 | 235 | 0.200 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2010 | 326 | 0.200 |
Why?
|
Chemoprevention | 2 | 2017 | 326 | 0.200 |
Why?
|
Uridine Monophosphate | 2 | 2019 | 68 | 0.200 |
Why?
|
Child, Preschool | 40 | 2022 | 42232 | 0.200 |
Why?
|
Myocardium | 1 | 2015 | 4725 | 0.200 |
Why?
|
Logistic Models | 9 | 2021 | 13255 | 0.200 |
Why?
|
Family Characteristics | 4 | 2020 | 1004 | 0.200 |
Why?
|
Inulin | 1 | 2021 | 67 | 0.190 |
Why?
|
Ischemia | 2 | 2022 | 1884 | 0.190 |
Why?
|
Regression Analysis | 9 | 2010 | 6345 | 0.190 |
Why?
|
Prebiotics | 1 | 2021 | 41 | 0.190 |
Why?
|
Air Pollutants, Occupational | 2 | 2014 | 407 | 0.190 |
Why?
|
Tomography, X-Ray Computed | 5 | 2019 | 20568 | 0.190 |
Why?
|
Airway Remodeling | 1 | 2022 | 133 | 0.190 |
Why?
|
Thromboembolism | 1 | 2008 | 995 | 0.190 |
Why?
|
Fluorenes | 2 | 2019 | 157 | 0.190 |
Why?
|
Sputum | 2 | 2021 | 506 | 0.190 |
Why?
|
Aged | 23 | 2024 | 169310 | 0.190 |
Why?
|
Salmonella typhi | 2 | 2021 | 198 | 0.190 |
Why?
|
Pandemics | 2 | 2023 | 8656 | 0.190 |
Why?
|
Insurance Claim Review | 1 | 2005 | 741 | 0.180 |
Why?
|
Body Fluids | 1 | 2022 | 320 | 0.180 |
Why?
|
Double-Blind Method | 23 | 2023 | 12341 | 0.180 |
Why?
|
Malpractice | 1 | 2005 | 556 | 0.180 |
Why?
|
Puberty | 2 | 2020 | 501 | 0.180 |
Why?
|
Confidence Intervals | 4 | 2013 | 2927 | 0.180 |
Why?
|
Indinavir | 4 | 2010 | 73 | 0.180 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2015 | 4575 | 0.180 |
Why?
|
Abortion, Spontaneous | 2 | 2024 | 533 | 0.180 |
Why?
|
Scleroderma, Localized | 1 | 2021 | 87 | 0.170 |
Why?
|
Rotavirus Vaccines | 1 | 2020 | 62 | 0.170 |
Why?
|
Tuberculin Test | 4 | 2023 | 206 | 0.170 |
Why?
|
Infection Control | 2 | 2020 | 982 | 0.170 |
Why?
|
Receptors, CCR5 | 5 | 2008 | 486 | 0.170 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2016 | 2518 | 0.170 |
Why?
|
Methylamines | 1 | 2021 | 136 | 0.170 |
Why?
|
Ebolavirus | 1 | 2022 | 251 | 0.170 |
Why?
|
Proportional Hazards Models | 11 | 2014 | 12463 | 0.170 |
Why?
|
Seasons | 4 | 2019 | 1520 | 0.170 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4948 | 0.170 |
Why?
|
Administration, Oral | 3 | 2024 | 4021 | 0.170 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2020 | 130 | 0.170 |
Why?
|
Child | 47 | 2022 | 80158 | 0.160 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2020 | 198 | 0.160 |
Why?
|
HIV Reverse Transcriptase | 4 | 2011 | 212 | 0.160 |
Why?
|
Occupational Exposure | 3 | 2014 | 1813 | 0.160 |
Why?
|
Adolescent | 45 | 2023 | 88326 | 0.160 |
Why?
|
Vaccines, Conjugate | 1 | 2020 | 328 | 0.160 |
Why?
|
Hair Follicle | 1 | 2021 | 211 | 0.160 |
Why?
|
Time Factors | 18 | 2023 | 39969 | 0.160 |
Why?
|
Pharmacokinetics | 2 | 2010 | 86 | 0.160 |
Why?
|
DNA, Viral | 4 | 2021 | 2202 | 0.160 |
Why?
|
Flavonols | 1 | 2019 | 85 | 0.160 |
Why?
|
England | 1 | 2020 | 526 | 0.160 |
Why?
|
Sensitivity and Specificity | 7 | 2020 | 14665 | 0.160 |
Why?
|
Young Adult | 25 | 2023 | 59260 | 0.160 |
Why?
|
Dietary Supplements | 4 | 2022 | 3415 | 0.160 |
Why?
|
Benzimidazoles | 3 | 2019 | 858 | 0.160 |
Why?
|
Virginia | 2 | 2015 | 116 | 0.160 |
Why?
|
Immunization, Passive | 2 | 2019 | 616 | 0.160 |
Why?
|
State Medicine | 1 | 2020 | 216 | 0.160 |
Why?
|
Leukocytes, Mononuclear | 3 | 2021 | 1844 | 0.150 |
Why?
|
Weight Gain | 4 | 2019 | 2348 | 0.150 |
Why?
|
Tanzania | 6 | 2023 | 1390 | 0.150 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2022 | 369 | 0.150 |
Why?
|
Morphogenesis | 2 | 2021 | 741 | 0.150 |
Why?
|
Genes, pol | 1 | 2018 | 52 | 0.150 |
Why?
|
Pancreatitis, Acute Necrotizing | 3 | 2007 | 173 | 0.150 |
Why?
|
Epidermis | 1 | 2021 | 528 | 0.150 |
Why?
|
Deoxycytidine | 6 | 2014 | 877 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2001 | 629 | 0.150 |
Why?
|
Amantadine | 1 | 2017 | 57 | 0.150 |
Why?
|
Risk Factors | 27 | 2023 | 74213 | 0.150 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2020 | 287 | 0.140 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2022 | 420 | 0.140 |
Why?
|
Anemia, Sickle Cell | 2 | 2016 | 1063 | 0.140 |
Why?
|
Multivariate Analysis | 14 | 2014 | 12059 | 0.140 |
Why?
|
Universities | 3 | 2022 | 993 | 0.140 |
Why?
|
Maternal-Fetal Exchange | 3 | 2016 | 461 | 0.140 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 397 | 0.140 |
Why?
|
Antibodies, Monoclonal | 9 | 2024 | 9177 | 0.140 |
Why?
|
Voice | 1 | 2020 | 268 | 0.140 |
Why?
|
Salvage Therapy | 2 | 2018 | 1263 | 0.140 |
Why?
|
Iloprost | 1 | 2016 | 25 | 0.140 |
Why?
|
Blood Component Transfusion | 1 | 2017 | 142 | 0.130 |
Why?
|
Statistics as Topic | 3 | 2000 | 2358 | 0.130 |
Why?
|
Anticoagulants | 2 | 2012 | 4812 | 0.130 |
Why?
|
Nucleosides | 2 | 2011 | 131 | 0.130 |
Why?
|
Child Development | 7 | 2014 | 2306 | 0.130 |
Why?
|
Risk Assessment | 7 | 2018 | 23996 | 0.130 |
Why?
|
Saquinavir | 2 | 2007 | 29 | 0.130 |
Why?
|
Disease Progression | 18 | 2020 | 13510 | 0.130 |
Why?
|
RNA | 5 | 2023 | 2725 | 0.130 |
Why?
|
Influenza A virus | 1 | 2019 | 458 | 0.130 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2008 | 2751 | 0.130 |
Why?
|
Longitudinal Studies | 7 | 2021 | 14608 | 0.130 |
Why?
|
Condoms | 2 | 2009 | 331 | 0.130 |
Why?
|
Interferons | 1 | 2019 | 706 | 0.130 |
Why?
|
Muscular Diseases | 2 | 2016 | 553 | 0.120 |
Why?
|
Liver Cirrhosis, Biliary | 2 | 1993 | 108 | 0.120 |
Why?
|
Drug Administration Schedule | 11 | 2019 | 4853 | 0.120 |
Why?
|
Prenatal Diagnosis | 2 | 2015 | 1265 | 0.120 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2016 | 103 | 0.120 |
Why?
|
Hospitalization | 7 | 2024 | 10721 | 0.120 |
Why?
|
Anti-Bacterial Agents | 5 | 2021 | 7406 | 0.120 |
Why?
|
Thailand | 4 | 2020 | 287 | 0.120 |
Why?
|
Multicenter Studies as Topic | 2 | 2017 | 1702 | 0.120 |
Why?
|
Lactobacillus acidophilus | 1 | 1994 | 21 | 0.120 |
Why?
|
Cohort Studies | 23 | 2020 | 41495 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 36426 | 0.120 |
Why?
|
Dependovirus | 1 | 2020 | 718 | 0.120 |
Why?
|
Drug Resistance, Bacterial | 2 | 2023 | 1048 | 0.120 |
Why?
|
Bacteriocins | 1 | 1994 | 88 | 0.120 |
Why?
|
Morbidity | 1 | 2020 | 1752 | 0.120 |
Why?
|
Skinfold Thickness | 2 | 2013 | 162 | 0.120 |
Why?
|
Neutropenia | 3 | 2017 | 885 | 0.120 |
Why?
|
Medication Adherence | 4 | 2021 | 2176 | 0.120 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2019 | 587 | 0.120 |
Why?
|
Wound Healing | 2 | 2021 | 2805 | 0.110 |
Why?
|
Adenine | 6 | 2018 | 987 | 0.110 |
Why?
|
AIDS Dementia Complex | 3 | 2004 | 153 | 0.110 |
Why?
|
Diarrhea | 1 | 2020 | 1318 | 0.110 |
Why?
|
Body Composition | 3 | 2019 | 2426 | 0.110 |
Why?
|
beta-Lactam Resistance | 1 | 2014 | 73 | 0.110 |
Why?
|
Drug Therapy | 1 | 2017 | 503 | 0.110 |
Why?
|
Acinetobacter Infections | 1 | 2014 | 73 | 0.110 |
Why?
|
beta-Thalassemia | 1 | 2016 | 236 | 0.110 |
Why?
|
Pancreatic Diseases | 1 | 1995 | 343 | 0.110 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2013 | 662 | 0.110 |
Why?
|
Microcirculation | 1 | 2018 | 1272 | 0.110 |
Why?
|
Atrial Fibrillation | 2 | 2012 | 5127 | 0.110 |
Why?
|
Genotype | 9 | 2017 | 12990 | 0.110 |
Why?
|
Carbapenems | 1 | 2014 | 123 | 0.110 |
Why?
|
Clofibrate | 1 | 1992 | 4 | 0.110 |
Why?
|
Pregnancy Outcome | 4 | 2024 | 2922 | 0.110 |
Why?
|
Genitalia, Male | 1 | 2013 | 87 | 0.110 |
Why?
|
Vitamin D Deficiency | 2 | 2014 | 1388 | 0.110 |
Why?
|
Europe | 3 | 2015 | 3420 | 0.110 |
Why?
|
Acinetobacter baumannii | 1 | 2014 | 118 | 0.110 |
Why?
|
Oxidative Stress | 3 | 2021 | 3113 | 0.100 |
Why?
|
Homicide | 1 | 2015 | 294 | 0.100 |
Why?
|
Cost-Benefit Analysis | 4 | 2015 | 5493 | 0.100 |
Why?
|
Cross-Sectional Studies | 11 | 2023 | 26129 | 0.100 |
Why?
|
Arthritis, Infectious | 1 | 2016 | 347 | 0.100 |
Why?
|
Bone Diseases | 1 | 2016 | 418 | 0.100 |
Why?
|
Survival | 1 | 1992 | 161 | 0.100 |
Why?
|
Safety | 1 | 2017 | 1149 | 0.100 |
Why?
|
Fires | 1 | 2013 | 171 | 0.100 |
Why?
|
Health Resources | 1 | 2018 | 935 | 0.100 |
Why?
|
Disease Reservoirs | 1 | 2012 | 121 | 0.100 |
Why?
|
Regeneration | 1 | 2021 | 1512 | 0.100 |
Why?
|
Reproducibility of Results | 7 | 2021 | 20100 | 0.100 |
Why?
|
Genitalia, Female | 1 | 2013 | 147 | 0.100 |
Why?
|
Alkynes | 4 | 2020 | 320 | 0.100 |
Why?
|
Prospective Studies | 22 | 2020 | 54423 | 0.100 |
Why?
|
Autoantibodies | 2 | 2021 | 2118 | 0.100 |
Why?
|
Carotenoids | 1 | 2015 | 621 | 0.100 |
Why?
|
Vasodilator Agents | 1 | 2016 | 973 | 0.100 |
Why?
|
Serum Albumin | 1 | 2015 | 672 | 0.100 |
Why?
|
Outpatients | 3 | 2024 | 1597 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2016 | 771 | 0.100 |
Why?
|
Drug Combinations | 4 | 2020 | 2048 | 0.100 |
Why?
|
United States | 22 | 2022 | 72340 | 0.100 |
Why?
|
Virus Replication | 4 | 2012 | 2435 | 0.090 |
Why?
|
Cyclopropanes | 4 | 2020 | 432 | 0.090 |
Why?
|
Likelihood Functions | 4 | 2013 | 992 | 0.090 |
Why?
|
Genetic Variation | 4 | 2018 | 6567 | 0.090 |
Why?
|
Social Support | 2 | 2014 | 2172 | 0.090 |
Why?
|
Lipids | 3 | 2016 | 3341 | 0.090 |
Why?
|
Choline | 1 | 2013 | 515 | 0.090 |
Why?
|
Pilot Projects | 3 | 2021 | 8633 | 0.090 |
Why?
|
Pesticides | 1 | 2013 | 296 | 0.090 |
Why?
|
Inhalation Exposure | 1 | 2014 | 432 | 0.090 |
Why?
|
Clinical Protocols | 3 | 2007 | 1440 | 0.090 |
Why?
|
Steroids | 1 | 2016 | 929 | 0.090 |
Why?
|
Prognosis | 8 | 2020 | 29629 | 0.090 |
Why?
|
Pain Measurement | 2 | 2020 | 3551 | 0.090 |
Why?
|
Mice, Transgenic | 2 | 2021 | 9542 | 0.090 |
Why?
|
Communication Disorders | 1 | 2011 | 50 | 0.090 |
Why?
|
Case-Control Studies | 9 | 2018 | 22176 | 0.090 |
Why?
|
Culture | 1 | 2014 | 623 | 0.090 |
Why?
|
Drugs, Generic | 1 | 2015 | 448 | 0.090 |
Why?
|
Waist Circumference | 2 | 2013 | 935 | 0.090 |
Why?
|
Activities of Daily Living | 2 | 2018 | 2421 | 0.090 |
Why?
|
Self Efficacy | 1 | 2014 | 638 | 0.090 |
Why?
|
Genetic Vectors | 1 | 2020 | 3396 | 0.090 |
Why?
|
Developing Countries | 6 | 2020 | 2885 | 0.090 |
Why?
|
Developmental Disabilities | 2 | 2016 | 1509 | 0.090 |
Why?
|
Microscopy | 1 | 2015 | 903 | 0.080 |
Why?
|
Ferritins | 2 | 2022 | 598 | 0.080 |
Why?
|
Algorithms | 4 | 2020 | 14033 | 0.080 |
Why?
|
Sexual Behavior | 3 | 2009 | 2180 | 0.080 |
Why?
|
Virology | 1 | 2009 | 75 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2018 | 6484 | 0.080 |
Why?
|
Interleukin-6 | 1 | 2019 | 3208 | 0.080 |
Why?
|
Sex Factors | 6 | 2020 | 10554 | 0.080 |
Why?
|
Methotrexate | 1 | 2015 | 1719 | 0.080 |
Why?
|
Microbial Sensitivity Tests | 4 | 2021 | 1936 | 0.080 |
Why?
|
Vitamin D | 2 | 2014 | 3303 | 0.080 |
Why?
|
Body Height | 4 | 2016 | 1570 | 0.080 |
Why?
|
Stavudine | 3 | 2005 | 85 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1422 | 0.080 |
Why?
|
Body Mass Index | 4 | 2015 | 12953 | 0.080 |
Why?
|
Hernia, Umbilical | 1 | 1989 | 102 | 0.080 |
Why?
|
Argentina | 2 | 2020 | 246 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 1112 | 0.080 |
Why?
|
Health Status | 2 | 2020 | 4077 | 0.080 |
Why?
|
Robotics | 1 | 2015 | 819 | 0.080 |
Why?
|
Linear Models | 6 | 2014 | 5872 | 0.080 |
Why?
|
Emotions | 1 | 2020 | 2739 | 0.080 |
Why?
|
Colorectal Neoplasms | 1 | 2008 | 6938 | 0.070 |
Why?
|
Inflammation | 5 | 2022 | 10774 | 0.070 |
Why?
|
HIV Core Protein p24 | 3 | 1998 | 245 | 0.070 |
Why?
|
Infant Formula | 1 | 2009 | 194 | 0.070 |
Why?
|
Follow-Up Studies | 17 | 2014 | 39106 | 0.070 |
Why?
|
Polymerase Chain Reaction | 4 | 2020 | 6075 | 0.070 |
Why?
|
Bacterial Infections | 1 | 1995 | 1391 | 0.070 |
Why?
|
Body Weight | 5 | 2016 | 4618 | 0.070 |
Why?
|
Exanthema | 1 | 2012 | 503 | 0.070 |
Why?
|
Anthropometry | 4 | 2016 | 1349 | 0.070 |
Why?
|
Environmental Monitoring | 1 | 2013 | 1460 | 0.070 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2006 | 710 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3600 | 0.070 |
Why?
|
Internet | 1 | 2019 | 3093 | 0.070 |
Why?
|
Rural Population | 1 | 1997 | 2287 | 0.070 |
Why?
|
Fatty Acids | 1 | 2015 | 1808 | 0.070 |
Why?
|
Hemoglobins | 3 | 2022 | 1526 | 0.070 |
Why?
|
Glucocorticoids | 2 | 2015 | 2161 | 0.070 |
Why?
|
Africa South of the Sahara | 3 | 2014 | 744 | 0.070 |
Why?
|
Lung | 3 | 2014 | 10002 | 0.070 |
Why?
|
Pre-Eclampsia | 2 | 2013 | 1231 | 0.070 |
Why?
|
Energy Metabolism | 1 | 1997 | 2882 | 0.070 |
Why?
|
Polymorphism, Genetic | 2 | 2008 | 4243 | 0.070 |
Why?
|
Spirometry | 3 | 2014 | 929 | 0.070 |
Why?
|
Age Factors | 9 | 2013 | 18399 | 0.070 |
Why?
|
Occlusive Dressings | 1 | 2006 | 52 | 0.070 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 983 | 0.070 |
Why?
|
Drug Monitoring | 2 | 2011 | 962 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2018 | 3575 | 0.070 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2011 | 600 | 0.070 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2006 | 25 | 0.060 |
Why?
|
Adiposity | 2 | 2013 | 1879 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2016 | 2319 | 0.060 |
Why?
|
Asthma | 3 | 2022 | 6234 | 0.060 |
Why?
|
Forecasting | 1 | 2015 | 2928 | 0.060 |
Why?
|
Placebos | 3 | 2010 | 1667 | 0.060 |
Why?
|
Homeostasis | 2 | 2015 | 3323 | 0.060 |
Why?
|
Half-Life | 2 | 2023 | 651 | 0.060 |
Why?
|
Kinetics | 2 | 2023 | 6374 | 0.060 |
Why?
|
Receptors, Virus | 1 | 2009 | 640 | 0.060 |
Why?
|
Cardiovascular Diseases | 4 | 2021 | 15502 | 0.060 |
Why?
|
Nutritional Support | 1 | 2007 | 173 | 0.060 |
Why?
|
Information Dissemination | 1 | 2014 | 1126 | 0.060 |
Why?
|
Hemocytes | 1 | 2005 | 44 | 0.060 |
Why?
|
Data Collection | 1 | 2015 | 3322 | 0.060 |
Why?
|
Herpes Genitalis | 1 | 2007 | 150 | 0.060 |
Why?
|
Mental Health | 1 | 2020 | 3250 | 0.060 |
Why?
|
Nitriles | 2 | 2022 | 971 | 0.060 |
Why?
|
Varicose Ulcer | 1 | 2006 | 55 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 1992 | 1141 | 0.060 |
Why?
|
Herpesvirus 2, Human | 1 | 2007 | 191 | 0.060 |
Why?
|
Virus Internalization | 1 | 2009 | 497 | 0.060 |
Why?
|
Ethics, Research | 1 | 2006 | 176 | 0.060 |
Why?
|
Pregnancy Trimester, First | 2 | 2024 | 907 | 0.060 |
Why?
|
Nurses | 1 | 2015 | 2478 | 0.060 |
Why?
|
Endoscopy | 1 | 2015 | 1851 | 0.060 |
Why?
|
Leptin | 1 | 2013 | 1597 | 0.060 |
Why?
|
Growth Disorders | 1 | 2010 | 655 | 0.060 |
Why?
|
Hyperbaric Oxygenation | 1 | 2006 | 165 | 0.060 |
Why?
|
Drug Costs | 2 | 2015 | 1183 | 0.060 |
Why?
|
Diet, Fat-Restricted | 1 | 2007 | 329 | 0.060 |
Why?
|
Patient Care Team | 1 | 2016 | 2521 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3206 | 0.060 |
Why?
|
Receptors, HIV | 1 | 2005 | 159 | 0.060 |
Why?
|
Protease Inhibitors | 2 | 2023 | 754 | 0.060 |
Why?
|
Obesity | 3 | 2019 | 12947 | 0.060 |
Why?
|
Iron | 2 | 2023 | 1793 | 0.060 |
Why?
|
Integumentary System | 1 | 2004 | 2 | 0.060 |
Why?
|
Cross-Over Studies | 3 | 2009 | 2079 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2021 | 12149 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2016 | 2057 | 0.060 |
Why?
|
Fetal Diseases | 1 | 1989 | 913 | 0.060 |
Why?
|
HIV Fusion Inhibitors | 1 | 2004 | 82 | 0.060 |
Why?
|
Aspartate Aminotransferases | 2 | 2018 | 416 | 0.060 |
Why?
|
Growth and Development | 1 | 2004 | 47 | 0.060 |
Why?
|
Occupations | 1 | 2006 | 515 | 0.060 |
Why?
|
Blood Pressure | 3 | 2014 | 8481 | 0.060 |
Why?
|
Antibiotic Prophylaxis | 2 | 2020 | 637 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2016 | 2244 | 0.060 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2008 | 1935 | 0.060 |
Why?
|
Mutation | 6 | 2022 | 30053 | 0.060 |
Why?
|
Restaurants | 1 | 2006 | 231 | 0.050 |
Why?
|
Prevalence | 6 | 2022 | 15733 | 0.050 |
Why?
|
Primary Health Care | 1 | 2020 | 4687 | 0.050 |
Why?
|
Control Groups | 1 | 2023 | 104 | 0.050 |
Why?
|
Chemokine CCL2 | 1 | 2006 | 605 | 0.050 |
Why?
|
Mitochondrial Diseases | 1 | 2007 | 343 | 0.050 |
Why?
|
Debridement | 1 | 2006 | 493 | 0.050 |
Why?
|
Herpesvirus 4, Human | 1 | 2009 | 1078 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2014 | 2091 | 0.050 |
Why?
|
Psoriasis | 1 | 2011 | 950 | 0.050 |
Why?
|
Dermatophagoides pteronyssinus | 1 | 2022 | 11 | 0.050 |
Why?
|
Internationality | 2 | 2018 | 1001 | 0.050 |
Why?
|
Alanine Transaminase | 2 | 2018 | 603 | 0.050 |
Why?
|
Analysis of Variance | 4 | 2007 | 6228 | 0.050 |
Why?
|
Mass Screening | 1 | 2018 | 5429 | 0.050 |
Why?
|
Hospitals, Psychiatric | 1 | 2004 | 321 | 0.050 |
Why?
|
Ultrasonography | 2 | 2021 | 5971 | 0.050 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2009 | 612 | 0.050 |
Why?
|
Antibodies, Neutralizing | 2 | 2022 | 1943 | 0.050 |
Why?
|
Vertebrates | 1 | 2004 | 227 | 0.050 |
Why?
|
Social Perception | 1 | 2006 | 433 | 0.050 |
Why?
|
Sampling Studies | 2 | 1997 | 615 | 0.050 |
Why?
|
Biological Evolution | 2 | 2009 | 1071 | 0.050 |
Why?
|
Sierra Leone | 1 | 2022 | 169 | 0.050 |
Why?
|
Pyroglyphidae | 1 | 2022 | 89 | 0.050 |
Why?
|
Abnormalities, Multiple | 1 | 1989 | 1423 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 3688 | 0.050 |
Why?
|
Receptors, CXCR4 | 1 | 2007 | 727 | 0.050 |
Why?
|
Chemokines, CXC | 1 | 2003 | 422 | 0.050 |
Why?
|
Cognition | 3 | 2013 | 6992 | 0.050 |
Why?
|
Malaria | 1 | 2011 | 1227 | 0.050 |
Why?
|
Pancreatitis | 2 | 2002 | 1096 | 0.050 |
Why?
|
Drug Resistance | 1 | 2008 | 1596 | 0.050 |
Why?
|
Mutation, Missense | 1 | 2011 | 2571 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2011 | 4740 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3826 | 0.050 |
Why?
|
Murinae | 1 | 2021 | 18 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4062 | 0.050 |
Why?
|
Depression, Postpartum | 1 | 2006 | 346 | 0.050 |
Why?
|
Forced Expiratory Volume | 4 | 2014 | 1814 | 0.050 |
Why?
|
Mathematics | 2 | 1995 | 707 | 0.050 |
Why?
|
Bacterial Proteins | 1 | 1994 | 3847 | 0.050 |
Why?
|
Retrospective Studies | 11 | 2023 | 80647 | 0.050 |
Why?
|
Adrenergic beta-Agonists | 2 | 1992 | 345 | 0.050 |
Why?
|
Africa | 2 | 2014 | 709 | 0.050 |
Why?
|
Diabetes Complications | 1 | 2008 | 1315 | 0.050 |
Why?
|
Diet Surveys | 2 | 2015 | 1162 | 0.050 |
Why?
|
Ceftriaxone | 1 | 2021 | 175 | 0.050 |
Why?
|
Platelet Count | 2 | 2013 | 781 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2005 | 928 | 0.040 |
Why?
|
Microscopy, Atomic Force | 1 | 2021 | 253 | 0.040 |
Why?
|
Spleen Focus-Forming Viruses | 1 | 2020 | 16 | 0.040 |
Why?
|
Biological Assay | 1 | 2023 | 626 | 0.040 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2022 | 459 | 0.040 |
Why?
|
Bone Density | 1 | 2013 | 3551 | 0.040 |
Why?
|
Alternative Splicing | 1 | 2005 | 1093 | 0.040 |
Why?
|
Clinical Competence | 1 | 2016 | 4793 | 0.040 |
Why?
|
Luciferases, Firefly | 1 | 2020 | 37 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 2 | 2013 | 731 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 2015 | 3763 | 0.040 |
Why?
|
Esophageal and Gastric Varices | 2 | 1993 | 208 | 0.040 |
Why?
|
Interleukin-4 | 1 | 2004 | 1149 | 0.040 |
Why?
|
Hemorrhage | 2 | 2012 | 3424 | 0.040 |
Why?
|
Semen | 1 | 2022 | 347 | 0.040 |
Why?
|
Computer Simulation | 3 | 2010 | 6241 | 0.040 |
Why?
|
Selection, Genetic | 2 | 2009 | 868 | 0.040 |
Why?
|
Chemokines | 1 | 2004 | 959 | 0.040 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 1999 | 119 | 0.040 |
Why?
|
Lymphoma | 1 | 2009 | 1901 | 0.040 |
Why?
|
Mothers | 3 | 2020 | 2198 | 0.040 |
Why?
|
Societies, Medical | 1 | 2012 | 3905 | 0.040 |
Why?
|
Plant Bark | 1 | 2019 | 9 | 0.040 |
Why?
|
Grape Seed Extract | 1 | 2019 | 11 | 0.040 |
Why?
|
Area Under Curve | 3 | 2010 | 1638 | 0.040 |
Why?
|
Pinus | 1 | 2019 | 16 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2021 | 5247 | 0.040 |
Why?
|
Dietary Fats | 1 | 2007 | 1995 | 0.040 |
Why?
|
Insulin Resistance | 3 | 2021 | 3964 | 0.040 |
Why?
|
Phosphates | 1 | 2022 | 770 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 220 | 0.040 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2022 | 629 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2023 | 426 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2013 | 4485 | 0.040 |
Why?
|
Smoking | 3 | 2013 | 9053 | 0.040 |
Why?
|
Length of Stay | 4 | 2017 | 6426 | 0.040 |
Why?
|
Survivors | 2 | 2022 | 2371 | 0.040 |
Why?
|
Time | 2 | 2007 | 546 | 0.040 |
Why?
|
Mice, Inbred C57BL | 3 | 2022 | 22174 | 0.040 |
Why?
|
Voice Quality | 1 | 2020 | 226 | 0.040 |
Why?
|
Microarray Analysis | 1 | 2021 | 750 | 0.040 |
Why?
|
CD4-CD8 Ratio | 2 | 2010 | 114 | 0.040 |
Why?
|
Exercise | 1 | 2015 | 5890 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2023 | 858 | 0.040 |
Why?
|
Oxazines | 1 | 2020 | 350 | 0.040 |
Why?
|
Pakistan | 1 | 2019 | 293 | 0.040 |
Why?
|
Escherichia coli | 3 | 2017 | 4217 | 0.040 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 2 | 2008 | 127 | 0.040 |
Why?
|
Fluid Therapy | 1 | 2002 | 579 | 0.040 |
Why?
|
Hedgehog Proteins | 1 | 2022 | 768 | 0.040 |
Why?
|
Pregnant Women | 1 | 2022 | 567 | 0.040 |
Why?
|
Pyridazines | 1 | 2019 | 202 | 0.040 |
Why?
|
Regenerative Medicine | 1 | 2021 | 306 | 0.040 |
Why?
|
Dideoxynucleosides | 1 | 1998 | 135 | 0.040 |
Why?
|
Patient Dropouts | 2 | 1997 | 412 | 0.040 |
Why?
|
Recurrence | 2 | 2022 | 8466 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2011 | 2947 | 0.040 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2013 | 1541 | 0.040 |
Why?
|
Telemedicine | 1 | 2015 | 3052 | 0.040 |
Why?
|
Pain | 2 | 2023 | 5073 | 0.040 |
Why?
|
Medical Errors | 1 | 2005 | 1263 | 0.040 |
Why?
|
Resuscitation | 1 | 2002 | 673 | 0.040 |
Why?
|
Odds Ratio | 3 | 2020 | 9647 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5440 | 0.040 |
Why?
|
Lactation | 1 | 2019 | 397 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2018 | 294 | 0.030 |
Why?
|
Models, Psychological | 1 | 2021 | 829 | 0.030 |
Why?
|
Panama | 1 | 2016 | 28 | 0.030 |
Why?
|
Intelligence | 2 | 2013 | 924 | 0.030 |
Why?
|
El Salvador | 1 | 2016 | 32 | 0.030 |
Why?
|
Diet | 1 | 2015 | 8075 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 3 | 2002 | 1881 | 0.030 |
Why?
|
Ethics, Medical | 2 | 1993 | 783 | 0.030 |
Why?
|
Drosophila melanogaster | 1 | 2005 | 1712 | 0.030 |
Why?
|
Hand | 1 | 2021 | 903 | 0.030 |
Why?
|
Hepatitis | 1 | 2018 | 228 | 0.030 |
Why?
|
Multiple Organ Failure | 2 | 2013 | 387 | 0.030 |
Why?
|
Drosophila Proteins | 1 | 2005 | 1699 | 0.030 |
Why?
|
Zalcitabine | 3 | 2000 | 43 | 0.030 |
Why?
|
South Africa | 2 | 2012 | 1843 | 0.030 |
Why?
|
Electric Impedance | 2 | 2010 | 757 | 0.030 |
Why?
|
HIV Antibodies | 1 | 2022 | 1303 | 0.030 |
Why?
|
Genome, Viral | 1 | 2019 | 667 | 0.030 |
Why?
|
Travel | 1 | 2021 | 796 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 597 | 0.030 |
Why?
|
Cytokines | 1 | 2010 | 7396 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2448 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3272 | 0.030 |
Why?
|
Bangladesh | 1 | 1997 | 736 | 0.030 |
Why?
|
Receptors, CCR2 | 2 | 2008 | 215 | 0.030 |
Why?
|
Patient Compliance | 4 | 2010 | 2690 | 0.030 |
Why?
|
Mexico | 1 | 2017 | 764 | 0.030 |
Why?
|
Arthrography | 1 | 2015 | 150 | 0.030 |
Why?
|
Risk | 3 | 2018 | 9610 | 0.030 |
Why?
|
Dyspnea | 1 | 2023 | 1347 | 0.030 |
Why?
|
Glucose Intolerance | 1 | 2019 | 575 | 0.030 |
Why?
|
Heart Diseases | 1 | 2008 | 2781 | 0.030 |
Why?
|
Pancreas | 1 | 2002 | 1691 | 0.030 |
Why?
|
Pyridines | 2 | 1997 | 2875 | 0.030 |
Why?
|
Pyridones | 1 | 2020 | 809 | 0.030 |
Why?
|
Headache | 1 | 2023 | 1256 | 0.030 |
Why?
|
Animals | 8 | 2022 | 168475 | 0.030 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 1995 | 186 | 0.030 |
Why?
|
Life Expectancy | 2 | 2012 | 1243 | 0.030 |
Why?
|
Health Care Costs | 1 | 2008 | 3242 | 0.030 |
Why?
|
Fetal Death | 2 | 2002 | 435 | 0.030 |
Why?
|
Brazil | 2 | 2009 | 1230 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2010 | 2850 | 0.030 |
Why?
|
Adipose Tissue | 2 | 2019 | 3313 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2139 | 0.030 |
Why?
|
Green Fluorescent Proteins | 1 | 2020 | 2065 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2012 | 10766 | 0.030 |
Why?
|
Electronics, Medical | 1 | 2014 | 72 | 0.030 |
Why?
|
Anistreplase | 1 | 1993 | 11 | 0.030 |
Why?
|
Predictive Value of Tests | 6 | 2013 | 15266 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 137 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 825 | 0.030 |
Why?
|
Fetal Blood | 2 | 2013 | 1347 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2008 | 13446 | 0.030 |
Why?
|
Pyrethrins | 1 | 2013 | 44 | 0.030 |
Why?
|
Immunity, Innate | 2 | 2022 | 3066 | 0.030 |
Why?
|
Australia | 1 | 2017 | 1250 | 0.030 |
Why?
|
Mycoses | 1 | 1997 | 386 | 0.030 |
Why?
|
Drug Interactions | 1 | 2018 | 1416 | 0.030 |
Why?
|
Biosensing Techniques | 1 | 2020 | 650 | 0.030 |
Why?
|
Monitoring, Immunologic | 1 | 1994 | 98 | 0.030 |
Why?
|
Triglycerides | 2 | 2014 | 2461 | 0.030 |
Why?
|
Blood Glucose | 1 | 2008 | 6391 | 0.030 |
Why?
|
Nutrition Policy | 1 | 1997 | 471 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2018 | 58984 | 0.030 |
Why?
|
Mice | 4 | 2022 | 81539 | 0.030 |
Why?
|
Placenta | 1 | 2022 | 1709 | 0.030 |
Why?
|
Hypertension | 2 | 2008 | 8540 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2022 | 3430 | 0.030 |
Why?
|
Autoimmunity | 1 | 2021 | 1356 | 0.030 |
Why?
|
Lactobacillus | 1 | 1994 | 212 | 0.030 |
Why?
|
Washington | 1 | 2013 | 315 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2022 | 2201 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2022 | 1749 | 0.030 |
Why?
|
Drug Discovery | 1 | 2021 | 1051 | 0.030 |
Why?
|
Molecular Sequence Data | 3 | 2008 | 17635 | 0.030 |
Why?
|
Betaine | 1 | 2013 | 90 | 0.030 |
Why?
|
Silicon Dioxide | 1 | 2014 | 216 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2007 | 793 | 0.030 |
Why?
|
Organophosphorus Compounds | 1 | 2013 | 206 | 0.030 |
Why?
|
Breath Tests | 1 | 2014 | 299 | 0.030 |
Why?
|
Retreatment | 1 | 2014 | 598 | 0.030 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4544 | 0.030 |
Why?
|
Software | 2 | 1999 | 4434 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2021 | 1902 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2023 | 2775 | 0.030 |
Why?
|
Acute Disease | 2 | 2019 | 7237 | 0.030 |
Why?
|
Pregnancy Trimester, Third | 1 | 2015 | 583 | 0.030 |
Why?
|
Eating | 1 | 2019 | 1539 | 0.020 |
Why?
|
Hepacivirus | 1 | 2019 | 1336 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
Cholesterol, LDL | 2 | 2014 | 2382 | 0.020 |
Why?
|
Models, Biological | 3 | 2012 | 9469 | 0.020 |
Why?
|
Injections, Subcutaneous | 2 | 2004 | 681 | 0.020 |
Why?
|
Bilirubin | 1 | 1993 | 436 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2018 | 1302 | 0.020 |
Why?
|
Vitamin A | 1 | 2015 | 613 | 0.020 |
Why?
|
Lung Diseases, Obstructive | 1 | 1992 | 308 | 0.020 |
Why?
|
Nutrition Assessment | 1 | 2015 | 728 | 0.020 |
Why?
|
Parity | 1 | 2015 | 927 | 0.020 |
Why?
|
Models, Economic | 1 | 2015 | 716 | 0.020 |
Why?
|
beta-Alanine | 1 | 2012 | 82 | 0.020 |
Why?
|
Comorbidity | 3 | 2016 | 10508 | 0.020 |
Why?
|
Maximum Tolerated Dose | 2 | 2005 | 883 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2015 | 675 | 0.020 |
Why?
|
Demography | 2 | 2006 | 1648 | 0.020 |
Why?
|
Heterozygote | 1 | 1998 | 2787 | 0.020 |
Why?
|
NF-kappa B | 1 | 2020 | 2490 | 0.020 |
Why?
|
Eclampsia | 1 | 2011 | 56 | 0.020 |
Why?
|
Aerosols | 1 | 2014 | 635 | 0.020 |
Why?
|
Feces | 1 | 2017 | 1497 | 0.020 |
Why?
|
Myocardial Infarction | 2 | 2007 | 11461 | 0.020 |
Why?
|
South America | 1 | 2011 | 179 | 0.020 |
Why?
|
California | 1 | 2015 | 1430 | 0.020 |
Why?
|
Vital Capacity | 1 | 2013 | 971 | 0.020 |
Why?
|
Parturition | 1 | 2014 | 448 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 1995 | 1626 | 0.020 |
Why?
|
Wechsler Scales | 1 | 2011 | 257 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2004 | 4580 | 0.020 |
Why?
|
Carbon Monoxide | 1 | 2014 | 547 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2005 | 4331 | 0.020 |
Why?
|
Species Specificity | 1 | 1994 | 2414 | 0.020 |
Why?
|
Carbon | 1 | 2014 | 666 | 0.020 |
Why?
|
Single-Blind Method | 2 | 2005 | 1574 | 0.020 |
Why?
|
International Normalized Ratio | 1 | 2012 | 382 | 0.020 |
Why?
|
Diastole | 1 | 1992 | 782 | 0.020 |
Why?
|
Bahamas | 1 | 2009 | 9 | 0.020 |
Why?
|
Vitamin B 12 | 1 | 2013 | 524 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1994 | 2496 | 0.020 |
Why?
|
Leukocyte Count | 1 | 1994 | 1596 | 0.020 |
Why?
|
Colombia | 1 | 2010 | 282 | 0.020 |
Why?
|
Atrial Flutter | 1 | 2012 | 252 | 0.020 |
Why?
|
Therapeutic Equivalency | 1 | 1989 | 134 | 0.020 |
Why?
|
Emotional Intelligence | 1 | 2011 | 135 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.020 |
Why?
|
Infant Mortality | 1 | 2014 | 759 | 0.020 |
Why?
|
Body Weights and Measures | 1 | 2010 | 208 | 0.020 |
Why?
|
Survival Rate | 3 | 2005 | 12723 | 0.020 |
Why?
|
Particle Size | 1 | 2014 | 1648 | 0.020 |
Why?
|
Virus Latency | 1 | 2012 | 363 | 0.020 |
Why?
|
Life Change Events | 1 | 2014 | 952 | 0.020 |
Why?
|
Vitamin K | 1 | 2012 | 318 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2014 | 1156 | 0.020 |
Why?
|
Viral Tropism | 1 | 2009 | 102 | 0.020 |
Why?
|
Physical Fitness | 1 | 2013 | 743 | 0.020 |
Why?
|
Personality Assessment | 1 | 2011 | 650 | 0.020 |
Why?
|
Electric Countershock | 1 | 2012 | 533 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 935 | 0.020 |
Why?
|
Somatostatin | 1 | 1990 | 447 | 0.020 |
Why?
|
Entropy | 1 | 2009 | 210 | 0.020 |
Why?
|
Public Health | 1 | 2022 | 2669 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 244 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 5790 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 1899 | 0.020 |
Why?
|
Safe Sex | 1 | 2009 | 144 | 0.020 |
Why?
|
Phenotype | 4 | 2002 | 16592 | 0.020 |
Why?
|
Violence | 1 | 2014 | 937 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2005 | 7859 | 0.020 |
Why?
|
Women's Health | 1 | 1997 | 2065 | 0.020 |
Why?
|
Personality Inventory | 1 | 2011 | 1019 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 1993 | 1241 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2014 | 1814 | 0.020 |
Why?
|
Death | 1 | 2012 | 676 | 0.020 |
Why?
|
India | 1 | 2014 | 2348 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2010 | 492 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 1997 | 2024 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2004 | 15936 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2021 | 11076 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21019 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1625 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2009 | 523 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2013 | 1188 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23447 | 0.020 |
Why?
|
North America | 1 | 2011 | 1276 | 0.020 |
Why?
|
Ticlopidine | 1 | 2012 | 730 | 0.020 |
Why?
|
Educational Status | 1 | 2015 | 2522 | 0.020 |
Why?
|
Prenatal Care | 1 | 2015 | 1141 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7581 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2013 | 1738 | 0.020 |
Why?
|
Firearms | 1 | 2014 | 626 | 0.020 |
Why?
|
Equipment Design | 1 | 2015 | 3511 | 0.020 |
Why?
|
Models, Cardiovascular | 1 | 1992 | 981 | 0.020 |
Why?
|
Social Responsibility | 1 | 1989 | 386 | 0.020 |
Why?
|
Insulin | 1 | 2021 | 6597 | 0.020 |
Why?
|
Resilience, Psychological | 1 | 2014 | 788 | 0.020 |
Why?
|
Peak Expiratory Flow Rate | 2 | 1999 | 144 | 0.020 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2006 | 114 | 0.020 |
Why?
|
Milk | 1 | 2009 | 443 | 0.020 |
Why?
|
Growth | 1 | 2008 | 365 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 416 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2008 | 437 | 0.020 |
Why?
|
Child Behavior Disorders | 1 | 2011 | 804 | 0.020 |
Why?
|
Neoplasms | 1 | 2015 | 22173 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2007 | 211 | 0.020 |
Why?
|
Folic Acid | 1 | 2013 | 1323 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7593 | 0.020 |
Why?
|
Hemolymph | 1 | 2005 | 27 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2017 | 2630 | 0.020 |
Why?
|
Fat Body | 1 | 2005 | 31 | 0.020 |
Why?
|
Nucleic Acid Conformation | 1 | 2009 | 902 | 0.020 |
Why?
|
Budesonide | 2 | 1999 | 157 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9420 | 0.020 |
Why?
|
Premenopause | 1 | 2009 | 1039 | 0.020 |
Why?
|
Disease Management | 1 | 2015 | 2508 | 0.020 |
Why?
|
Atherosclerosis | 1 | 2021 | 3407 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2009 | 2180 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 1993 | 2064 | 0.010 |
Why?
|
Students | 1 | 2014 | 1741 | 0.010 |
Why?
|
Viral Envelope Proteins | 1 | 2008 | 640 | 0.010 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2007 | 506 | 0.010 |
Why?
|
Psychology | 1 | 2006 | 356 | 0.010 |
Why?
|
Mental Disorders | 1 | 2004 | 6845 | 0.010 |
Why?
|
Random Allocation | 1 | 1988 | 2395 | 0.010 |
Why?
|
Health Surveys | 1 | 2014 | 4061 | 0.010 |
Why?
|
Sexual Partners | 1 | 2009 | 796 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2008 | 2748 | 0.010 |
Why?
|
Checklist | 1 | 2011 | 827 | 0.010 |
Why?
|
DNA Primers | 1 | 2008 | 2820 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2007 | 1991 | 0.010 |
Why?
|
Lipoproteins, HDL | 1 | 2008 | 676 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2008 | 1519 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1990 | 1116 | 0.010 |
Why?
|
Cholesterol | 1 | 1992 | 2905 | 0.010 |
Why?
|
New England | 1 | 2006 | 1054 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6766 | 0.010 |
Why?
|
Memory | 1 | 2013 | 2193 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12690 | 0.010 |
Why?
|
Cause of Death | 1 | 1993 | 3683 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2015 | 4176 | 0.010 |
Why?
|
Thymidine | 1 | 2002 | 299 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 2004 | 397 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 1987 | 756 | 0.010 |
Why?
|
HIV Envelope Protein gp41 | 1 | 2004 | 303 | 0.010 |
Why?
|
Apgar Score | 1 | 2002 | 126 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2005 | 852 | 0.010 |
Why?
|
Glucose | 1 | 2014 | 4347 | 0.010 |
Why?
|
Chemokine CXCL12 | 1 | 2003 | 454 | 0.010 |
Why?
|
Psychometrics | 1 | 2011 | 3065 | 0.010 |
Why?
|
Nutrition Surveys | 1 | 2008 | 1733 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2005 | 1699 | 0.010 |
Why?
|
Labor, Obstetric | 1 | 2004 | 323 | 0.010 |
Why?
|
Cytomegalovirus Infections | 1 | 1987 | 831 | 0.010 |
Why?
|
Animals, Genetically Modified | 1 | 2005 | 1561 | 0.010 |
Why?
|
Hematocrit | 1 | 2002 | 623 | 0.010 |
Why?
|
Postmenopause | 1 | 2009 | 2513 | 0.010 |
Why?
|
Aspirin | 1 | 2012 | 3133 | 0.010 |
Why?
|
Alleles | 1 | 2011 | 6864 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8833 | 0.010 |
Why?
|
Chronic Disease | 1 | 2015 | 9319 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4576 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2007 | 1530 | 0.010 |
Why?
|
Phagocytosis | 1 | 2005 | 1528 | 0.010 |
Why?
|
Administration, Inhalation | 2 | 1992 | 1157 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2005 | 1601 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 1987 | 2693 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2005 | 1410 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7828 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11742 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2005 | 3792 | 0.010 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 1998 | 151 | 0.010 |
Why?
|
Urban Population | 1 | 2006 | 2036 | 0.010 |
Why?
|
Liver | 2 | 2006 | 7528 | 0.010 |
Why?
|
Base Sequence | 1 | 2009 | 12441 | 0.010 |
Why?
|
Long-Term Care | 1 | 2002 | 633 | 0.010 |
Why?
|
Giant Cells | 1 | 1998 | 188 | 0.010 |
Why?
|
Necrosis | 1 | 2002 | 1611 | 0.010 |
Why?
|
Infant, Low Birth Weight | 1 | 2002 | 870 | 0.010 |
Why?
|
Tissue Donors | 1 | 1987 | 2332 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3779 | 0.010 |
Why?
|
Postpartum Period | 1 | 2004 | 1175 | 0.010 |
Why?
|
Motor Activity | 1 | 2007 | 2715 | 0.010 |
Why?
|
Creatine Kinase | 1 | 1998 | 685 | 0.010 |
Why?
|
RNA Interference | 1 | 2005 | 2832 | 0.010 |
Why?
|
Delivery, Obstetric | 1 | 2004 | 941 | 0.010 |
Why?
|
Gestational Age | 1 | 2005 | 3577 | 0.010 |
Why?
|
Decision Making | 1 | 2009 | 3929 | 0.010 |
Why?
|
Erythema | 1 | 1996 | 262 | 0.010 |
Why?
|
Treatment Refusal | 1 | 1997 | 429 | 0.010 |
Why?
|
Medical Oncology | 1 | 2006 | 2321 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2007 | 4028 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2004 | 5870 | 0.010 |
Why?
|
Boston | 1 | 2006 | 9327 | 0.010 |
Why?
|
Terbutaline | 1 | 1992 | 23 | 0.010 |
Why?
|
Ipratropium | 1 | 1992 | 19 | 0.010 |
Why?
|
Beclomethasone | 1 | 1992 | 38 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7391 | 0.010 |
Why?
|
Pregnenediones | 1 | 1992 | 29 | 0.010 |
Why?
|
Infant, Premature | 1 | 2002 | 2107 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2004 | 5112 | 0.010 |
Why?
|
Albuterol | 1 | 1992 | 213 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15601 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1992 | 641 | 0.010 |
Why?
|
Respiratory Hypersensitivity | 1 | 1992 | 273 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 1999 | 1809 | 0.010 |
Why?
|
Balloon Occlusion | 1 | 1990 | 125 | 0.010 |
Why?
|
Bronchodilator Agents | 1 | 1992 | 512 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1990 | 1379 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2002 | 18966 | 0.000 |
Why?
|
Neurons | 1 | 2005 | 9463 | 0.000 |
Why?
|
Catheterization | 1 | 1990 | 1428 | 0.000 |
Why?
|
Aging | 1 | 2003 | 8710 | 0.000 |
Why?
|
Blood Transfusion | 1 | 1990 | 1301 | 0.000 |
Why?
|
Immunization | 1 | 1987 | 1227 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1990 | 8527 | 0.000 |
Why?
|
Brain | 1 | 2005 | 27121 | 0.000 |
Why?
|
Periodicals as Topic | 1 | 1987 | 1463 | 0.000 |
Why?
|
Pneumonia | 1 | 1987 | 2143 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1987 | 10194 | 0.000 |
Why?
|